Published : Oct-2017
No. of Pages : 188
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 9
2.1 Melanoma Diagnostic Tests Overview 9
3 Products under Development 10
3.1 Melanoma Diagnostic Tests - Pipeline Products by Stage of Development 10
3.2 Melanoma Diagnostic Tests - Pipeline Products by Territory 11
3.3 Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path 12
3.4 Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date 13
3.5 Melanoma Diagnostic Tests - Ongoing Clinical Trials 14
4 Melanoma Diagnostic Tests - Pipeline Products under Development by Companies 15
4.1 Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development 15
4.2 Melanoma Diagnostic Tests - Pipeline Products by Stage of Development 17
5 Melanoma Diagnostic Tests Companies and Product Overview 19
5.1 Abbott Diagnostics Company Overview 19
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 19
5.2 Adaptive Biotechnologies Corp Company Overview 20
5.2.1 Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 20
5.3 Agilent Technologies Inc Company Overview 21
5.3.1 Agilent Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 21
5.4 BioMark Diagnostics Inc. Company Overview 22
5.4.1 BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
5.5 BioMarker Strategies LLC Company Overview 23
5.5.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 23
5.6 Biosceptre International Ltd Company Overview 25
5.6.1 Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
5.7 Ceres Nanosciences Inc Company Overview 26
5.7.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 26
5.8 Dana-Farber Cancer Institute Inc Company Overview 27
5.8.1 Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 27
5.9 Digna Biotech SL Company Overview 28
5.9.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 28
5.10 Exosomics Siena SpA Company Overview 29
5.10.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 29
5.11 Genomic Health Inc Company Overview 30
5.11.1 Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview 30
5.12 Hospital Universitario Cruces Company Overview 31
5.12.1 Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview 31
5.13 Hummingbird Diagnostics GmbH Company Overview 32
5.13.1 Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 32
5.14 ImmunID SAS Company Overview 33
5.14.1 ImmunID SAS Pipeline Products & Ongoing Clinical Trials Overview 33
5.15 Institut Pasteur Company Overview 36
5.15.1 Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview 36
5.16 InterGenetics Inc Company Overview 37
5.16.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 37
5.17 IV Diagnostics Inc Company Overview 38
5.17.1 IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
5.18 John Hopkins University Company Overview 39
5.18.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 39
5.19 Louisville Bioscience, Inc. Company Overview 40
5.19.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
5.20 MDNA Life Sciences Inc Company Overview 41
5.20.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 41
5.21 Melanovus Oncology Inc Company Overview 42
5.21.1 Melanovus Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 42
5.22 Memorial Sloan Kettering Cancer Center Company Overview 43
5.22.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 43
5.23 MyCardio LLC Company Overview 44
5.23.1 MyCardio LLC Pipeline Products & Ongoing Clinical Trials Overview 44
5.24 Orion Genomics LLC Company Overview 45
5.24.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45
5.25 Oryzon Genomics SA Company Overview 46
5.25.1 Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview 46
5.26 Pacific Edge Ltd Company Overview 48
5.26.1 Pacific Edge Ltd Pipeline Products & Ongoing Clinical Trials Overview 48
5.27 Protea Biosciences Group Inc Company Overview 49
5.27.1 Protea Biosciences Group Inc Pipeline Products & Ongoing Clinical Trials Overview 49
5.28 Qiagen NV Company Overview 52
5.28.1 Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview 52
5.29 Roche Diagnostics International Ltd Company Overview 54
5.29.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
5.30 Rosetta Genomics Ltd Company Overview 58
5.30.1 Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 58
5.31 Sividon Diagnostics GmbH Company Overview 59
5.31.1 Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 59
5.32 SomaLogic Inc Company Overview 60
5.32.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 60
5.33 Treos Bio Inc Company Overview 61
5.33.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 61
5.34 University of California San Francisco Company Overview 62
5.34.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 62
5.35 University of Louisville Company Overview 63
5.35.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 63
5.36 University of Maryland Baltimore Company Overview 64
5.36.1 University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview 64
5.37 Vanderbilt University Company Overview 65
5.37.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 65
5.38 Zymera, Inc Company Overview 66
5.38.1 Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview 66
6 Melanoma Diagnostic Tests - Recent Developments 67
6.1 Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses 67
6.2 Aug 31, 2017: BioMarker Strategies Announces Two New Patents Granted in Japan, For the Company's Core Diagnostics Technology PathMAP 67
6.3 Aug 30, 2017: bioMerieux - First-Half 2017 Results 68
6.4 Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy 71
6.5 Aug 22, 2017: Protea Expands Clinical Study for New Melanoma Test 71
6.6 Aug 15, 2017: Agilent Technologies Reports Third-Quarter Fiscal Year 2017 Financial Results 72
6.7 Aug 08, 2017: HTG Molecular Diagnostics Reports Second Quarter 2017 Results 73
6.8 Aug 01, 2017: Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress 73
6.9 Jul 31, 2017: AtCor Signs New Agreement Major entry point into New York health systems market 75
6.10 Jul 28, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017 75
6.11 Jul 27, 2017: Adaptive Biotechnologies Expands Leadership to Bolster Integration of Immune Profiling into Clinical Care Setting 77
6.12 Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 77
6.13 Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 81
6.14 Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 87
6.15 Jul 25, 2017: Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook 87
6.16 Jul 21, 2017: GSK announces Board and Committee changes 87
6.17 Jul 20, 2017: bioMerieux - Second-Quarter 2017 Business Review 88
6.18 Jul 20, 2017: Professor John Spencer's Lab to Carry Out Vital Skin Cancer Research Thanks to New Grant 90
6.19 Jul 18, 2017: Hans E. Bishop to Join Agilent's Board of Directors 91
6.20 Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 92
6.21 Jun 19, 2017: GSK confirms start date for Luke Miels 92
6.22 Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 92
6.23 Jun 01, 2017: MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries 92
6.24 May 22, 2017: Agilent Technologies Reports Second-Quarter Fiscal Year 2017 Financial Results 93
6.25 May 16, 2017: Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department 94
6.26 May 15, 2017: HTG Molecular Diagnostics Reports First Quarter 2017 Results 94
6.27 May 09, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017 95
6.28 May 09, 2017: Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress 97
6.29 May 04, 2017: Agilent Technologies Receives Multiple Awards at Scientific Conference in China 98
6.30 May 02, 2017: QIAGEN reports results for first quarter 2017 99
6.31 May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 101
6.32 May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan 103
6.33 Apr 26, 2017: GSK delivers another quarter of continued progress 103
6.34 Apr 20, 2017: Quest Diagnostics Reports First Quarter 2017 Financial Results, Raises 2017 Financial Outlook 107
6.35 Apr 20, 2017: bioMerieux - First-Quarter 2017 Business Review 107
6.36 Apr 18, 2017: Protea Announces 2016 Year End Results 109
6.37 Apr 05, 2017: SomaLogic announces the appointment of long-time Board member as Chief Executive Officer 110
6.38 Apr 04, 2017: GSK responds to Cyclone Debbie 111
6.39 Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results 111
6.40 Mar 23, 2017: HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results 114
6.41 Mar 20, 2017: Agilent Technologies Hires Samraat "Sam" Raha to Head Strategy and Corporate Development 115
6.42 Mar 15, 2017: Agilent Technologies Board of Directors Elects Koh Boon Hwee as New Chairman 115
6.43 Mar 14, 2017: Agilent Technologies Receives 2017 Scientists' Choice Award for Best Webinar Series 116
6.44 Mar 07, 2017: HTG Molecular Diagnostics Appoints New Chair of the Board of Directors 117
6.45 Mar 01, 2017: bioMerieux - 2016 Financial Results 117
6.46 Feb 24, 2017: ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016 121
6.47 Feb 21, 2017: Agilent Technologies Receives Dow's Western Canada Science and Technical Excellence Conference Awards (WesTEC) for Technical Excellence and Innovation 122
6.48 Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 122
6.49 Feb 14, 2017: Agilent Technologies Reports First-Quarter 2017 Results 123
6.50 Feb 14, 2017: Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook 124
6.51 Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 126
6.52 Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 145
6.53 Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 146
6.54 Jan 26, 2017: Quest Diagnostics Reports Fourth Quarter And Full Year 2016 Financial Results; Provides Guidance For Full Year 2017 150
6.55 Jan 26, 2017: Quest Diagnostics Partners With Montefiore Health System to Deliver High-Value, Innovative Laboratory Services 151
6.56 Jan 19, 2017: bioMerieux - Fourth-Quarter 2016 Business Review 151
6.57 Jan 19, 2017: Abbas Hussain to leave GSK 153
6.58 Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 154
6.59 Dec 21, 2016: Agilent Technologies Receives Top Innovation Award from The Analytical Scientist 155
6.60 Dec 19, 2016: GSK announces Board changes 155
6.61 Dec 15, 2016: Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board 156
6.62 Nov 24, 2016: Pacific Edge Interim Results to 30 September 2016 156
6.63 Nov 22, 2016: Protea Announces Third Quarter 2016 Results 158
6.64 Nov 15, 2016: Agilent Technologies Reports Fourth-Quarter 2016 Results 158
6.65 Nov 14, 2016: HTG Molecular Diagnostics Reports Third Quarter 2016 Results 159
6.66 Nov 11, 2016: Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day 160
6.67 Nov 10, 2016: Protea Appoints David Halverson As President 161
6.68 Nov 07, 2016: Pierre Boulud appointed Corporate Vice Presidentof the Asia Pacific region at bioMerieux 162
6.69 Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016 162
6.70 Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017 165
6.71 Nov 01, 2016: Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results 166
6.72 Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results 167
6.73 Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 168
6.74 Oct 24, 2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016 175
6.75 Oct 20, 2016: bioMerieux-Business Review for the nine months ended September 30, 2016 176
6.76 Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results 179
6.77 Oct 20, 2016: Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer 180
6.78 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 181
6.79 Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy 182
6.80 Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results 182
7 Appendix 185
7.1 Methodology 185
7.2 About GlobalData 188
7.3 Contact Us 188
7.4 Disclaimer 188
1.1 List of Tables
Table 1: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development 10
Table 2: Melanoma Diagnostic Tests - Pipeline Products by Territory 11
Table 3: Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path 12
Table 4: Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date 13
Table 5: Melanoma Diagnostic Tests - Ongoing Clinical Trials 14
Table 6: Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development 15
Table 7: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development 17
Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 19
Table 9: MAGE-A3 Companion Diagnostic Assay - Melanoma - Product Status 19
Table 10: MAGE-A3 Companion Diagnostic Assay - Melanoma - Product Description 19
Table 11: Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 20
Table 12: Companion Diagnostic Test - Melanoma Cancer - Product Status 20
Table 13: Companion Diagnostic Test - Melanoma Cancer - Product Description 20
Table 14: Agilent Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 21
Table 15: MK-3475 Companion Diagnostic Test - Product Status 21
Table 16: MK-3475 Companion Diagnostic Test - Product Description 21
Table 17: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 22
Table 18: Metabolomics-Based Diagnostic Assay - Melanoma - Product Status 22
Table 19: Metabolomics-Based Diagnostic Assay - Melanoma - Product Description 22
Table 20: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 23
Table 21: Ex Vivo Biomarker Test - Melanoma - Product Status 23
Table 22: Ex Vivo Biomarker Test - Melanoma - Product Description 23
Table 23: PathMAP - Product Status 24
Table 24: PathMAP - Product Description 24
Table 25: Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
Table 26: Skin Cancer IHC Diagnostic Test - Product Status 25
Table 27: Skin Cancer IHC Diagnostic Test - Product Description 25
Table 28: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 26
Table 29: Melanoma Skin Patch Sweat Test - Product Status 26
Table 30: Melanoma Skin Patch Sweat Test - Product Description 26
Table 31: Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 27
Table 32: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Status 27
Table 33: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Description 27
Table 34: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 28
Table 35: Melanoma Test - Product Status 28
Table 36: Melanoma Test - Product Description 28
Table 37: Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 29
Table 38: ExoTEST Melanoma - Product Status 29
Table 39: ExoTEST Melanoma - Product Description 29
Table 40: Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview 30
Table 41: Prognostic Test - Melanoma - Product Status 30
Table 42: Prognostic Test - Melanoma - Product Description 30
Table 43: Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview 31
Table 44: Diagnostic Assay - Melanoma - Product Status 31
Table 45: Diagnostic Assay - Melanoma - Product Description 31
Table 46: Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 32
Table 47: Diagnostic Test - Melanoma - Product Status 32
Table 48: Diagnostic Test - Melanoma - Product Description 32
Table 49: ImmunID SAS Pipeline Products & Ongoing Clinical Trials Overview 33
Table 50: ImmunTraCkeR - Metastatic Melanoma - Product Status 33
Table 51: ImmunTraCkeR - Metastatic Melanoma - Product Description 33
Table 52: ImmunID SAS - Ongoing Clinical Trials Overview 34
Table 53: ImmunTraCkeR - Metastatic Melanoma - Multicenter Clinical Study to Assess the Use of Immune Competence Profiles evaluated by ImmunTracker in Metastatic Melanoma Subjects Treated with an Immune Checkpoint Inhibitor 35
Table 54: ImmunTraCkeR - Metastatic Melanoma - Validation of ImmunTraCkeR in Metastatic Melanoma Patients - A Medico-economic Clinical Study 35
Table 55: Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview 36
Table 56: Diagnostic Test - Melanoma - Product Status 36
Table 57: Diagnostic Test - Melanoma - Product Description 36
Table 58: InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 37
Table 59: OncoVue Skin - Product Status 37
Table 60: OncoVue Skin - Product Description 37
Table 61: IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 38
Table 62: IVDiagnostics Diagnostic Test - Melanoma - Product Status 38
Table 63: IVDiagnostics Diagnostic Test - Melanoma - Product Description 38
Table 64: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 39
Table 65: Biomarker Based Diagnostic Assay - Melanoma - Product Status 39
Table 66: Biomarker Based Diagnostic Assay - Melanoma - Product Description 39
Table 67: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
Table 68: Melanoma Remission pT Test - Product Status 40
Table 69: Melanoma Remission pT Test - Product Description 40
Table 70: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 41
Table 71: Diagnostic Test - Melanoma - Product Status 41
Table 72: Diagnostic Test - Melanoma - Product Description 41
Table 73: Melanovus Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 42
Table 74: Companion Diagnostic Test - Melanoma - Product Status 42
Table 75: Companion Diagnostic Test - Melanoma - Product Description 42
Table 76: Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 43
Table 77: Melanoma Biomarker - Resistance to RAF Inhibitors - Product Status 43
Table 78: Melanoma Biomarker - Resistance to RAF Inhibitors - Product Description 43
Table 79: MyCardio LLC Pipeline Products & Ongoing Clinical Trials Overview 44
Table 80: Diagnostic Assay - Melanoma - Product Status 44
Table 81: Diagnostic Assay - Melanoma - Product Description 44
Table 82: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45
Table 83: Diagnostic Assay - Melanoma - Product Status 45
Table 84: Diagnostic Assay - Melanoma - Product Description 45
Table 85: Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview 46
Table 86: Diagnostic Assay - Melanoma Cancer - Product Status 46
Table 87: Diagnostic Assay - Melanoma Cancer - Product Description 46
Table 88: Prognostic Assay - Melanoma Cancer - Product Status 47
Table 89: Prognostic Assay - Melanoma Cancer - Product Description 47
Table 90: Pacific Edge Ltd Pipeline Products & Ongoing Clinical Trials Overview 48
Table 91: Prognostic Assay - Melanoma - Product Status 48
Table 92: Prognostic Assay - Melanoma - Product Description 48
Table 93: Protea Biosciences Group Inc Pipeline Products & Ongoing Clinical Trials Overview 49
Table 94: Mass Spectrometry Imaging Based Test - Malignant Melanoma - Product Status 49
Table 95: Mass Spectrometry Imaging Based Test - Malignant Melanoma - Product Description 49
Table 96: Protea Biosciences Group Inc - Ongoing Clinical Trials Overview 50
Table 97: Mass Spectrometry Imaging Based Test - Malignant Melanoma - Clinical Research Study for New Molecular Imaging Test for the Differential Diagnosis of Malignant Melanoma 51
Table 98: Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview 52
Table 99: Companion Diagnostic Test - Binimetinib - Product Status 52
Table 100: Companion Diagnostic Test - Binimetinib - Product Description 52
Table 101: QIAsymphony - NRAS Assay - Product Status 53
Table 102: QIAsymphony - NRAS Assay - Product Description 53
Table 103: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
Table 104: Cobimetinib Companion Diagnostic Assay - Product Status 54
Table 105: Cobimetinib Companion Diagnostic Assay - Product Description 54
Table 106: Companion Diagnostic Test - MEK 0973 - Product Status 55
Table 107: Companion Diagnostic Test - MEK 0973 - Product Description 55
Table 108: ETBR ADC Companion Diagnostic Test - Product Status 55
Table 109: ETBR ADC Companion Diagnostic Test - Product Description 56
Table 110: PDL1+Zelboraf Companion Diagnostic Test - Product Status 56
Table 111: PDL1+Zelboraf Companion Diagnostic Test - Product Description 56
Table 112: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Status 57
Table 113: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Description 57
Table 114: Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 58
Table 115: microRNA-Based Diagnostic Test - Melanoma - Product Status 58
Table 116: microRNA-Based Diagnostic Test - Melanoma - Product Description 58
Table 117: Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 59
Table 118: Diagnostic Assay - Melanoma - Product Status 59
Table 119: Diagnostic Assay - Melanoma - Product Description 59
Table 120: SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 60
Table 121: SOMAscan Assay - Melanoma - Product Status 60
Table 122: SOMAscan Assay - Melanoma - Product Description 60
Table 123: Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 61
Table 124: PolyPEPI 613 CDx - Product Status 61
Table 125: PolyPEPI 613 CDx - Product Description 61
Table 126: University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 62
Table 127: Diagnostic Assay - Uveal Melanoma - Product Status 62
Table 128: Diagnostic Assay - Uveal Melanoma - Product Description 62
Table 129: University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 63
Table 130: Melanoma Sentinel Lymph Node Biomarker Test - Product Status 63
Table 131: Melanoma Sentinel Lymph Node Biomarker Test - Product Description 63
Table 132: University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview 64
Table 133: Prognostic Biomarker Test - Melanoma - Product Status 64
Table 134: Prognostic Biomarker Test - Melanoma - Product Description 64
Table 135: Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 65
Table 136: Companion Diagnostic Assay - Melanoma - Product Status 65
Table 137: Companion Diagnostic Assay - Melanoma - Product Description 65
Table 138: Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview 66
Table 139: Prognostic Assay - Melanoma - Product Status 66
Table 140: Prognostic Assay - Melanoma - Product Description 66
Table 141: Glossary 187
1.2 List of Figures
Figure 1: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development 10
Figure 2: Melanoma Diagnostic Tests - Pipeline Products by Territory 11
Figure 3: Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path 12
Figure 4: Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date 13
Figure 5: Melanoma Diagnostic Tests - Ongoing Clinical Trials 14
